These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38038260)

  • 1. Using energy to go downhill-a genoprotective role for ATPase activity in DNA topoisomerase II.
    Bandak AF; Blower TR; Nitiss KC; Shah V; Nitiss JL; Berger JM
    Nucleic Acids Res; 2024 Feb; 52(3):1313-1324. PubMed ID: 38038260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using energy to go downhill - a genoprotective role for ATPase activity in DNA topoisomerase II.
    Bandak AF; Blower TR; Nitiss KC; Shah V; Nitiss JL; Berger JM
    bioRxiv; 2023 Jun; ():. PubMed ID: 37425896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of the DNA-dependent ATPase activity of human DNA topoisomerase IIbeta: mutation of Ser165 in the ATPase domain reduces the ATPase activity and abolishes the in vivo complementation ability.
    West KL; Turnbull RM; Willmore E; Lakey JH; Austin CA
    Nucleic Acids Res; 2002 Dec; 30(24):5416-24. PubMed ID: 12490710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-function analysis of the ATPase domain of African swine fever virus topoisomerase.
    Kuang W; Zhao Y; Li J; Deng Z
    mBio; 2024 Apr; 15(4):e0308623. PubMed ID: 38411066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naturally mutagenic sequence diversity in a human type II topoisomerase.
    Bandak AF; Blower TR; Nitiss KC; Gupta R; Lau AY; Guha R; Nitiss JL; Berger JM
    Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302064120. PubMed ID: 37406101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
    Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
    Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Communication between the ATPase and cleavage/religation domains of human topoisomerase IIalpha.
    Bjergbaek L; Kingma P; Nielsen IS; Wang Y; Westergaard O; Osheroff N; Andersen AH
    J Biol Chem; 2000 Apr; 275(17):13041-8. PubMed ID: 10777608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of Escherichia coli topoisomerase IV. II. ATPase negative mutants of parE induce hyper-DNA cleavage.
    Nurse P; Bahng S; Mossessova E; Marians KJ
    J Biol Chem; 2000 Feb; 275(6):4104-11. PubMed ID: 10660570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.
    Robinson MJ; Osheroff N
    Biochemistry; 1991 Feb; 30(7):1807-13. PubMed ID: 1847075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
    Sehested M; Jensen PB
    Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism.
    Schoeffler AJ; Berger JM
    Biochem Soc Trans; 2005 Dec; 33(Pt 6):1465-70. PubMed ID: 16246147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the C-terminal domain on the interaction of human DNA topoisomerase II α and β with DNA.
    Gilroy KL; Austin CA
    PLoS One; 2011 Feb; 6(2):e14693. PubMed ID: 21358820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
    Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
    Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
    Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
    Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase VI senses and exploits both DNA crossings and bends to facilitate strand passage.
    Wendorff TJ; Berger JM
    Elife; 2018 Mar; 7():. PubMed ID: 29595473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of casein kinase II-mediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis.
    Corbett AH; DeVore RF; Osheroff N
    J Biol Chem; 1992 Oct; 267(28):20513-8. PubMed ID: 1328202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
    Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
    Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutagenesis of E477 or K505 in the B' domain of human topoisomerase II beta increases the requirement for magnesium ions during strand passage.
    West KL; Meczes EL; Thorn R; Turnbull RM; Marshall R; Austin CA
    Biochemistry; 2000 Feb; 39(6):1223-33. PubMed ID: 10684600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide.
    Sengupta T; Mukherjee M; Das A; Mandal C; Das R; Mukherjee T; Majumder HK
    Biochem J; 2005 Sep; 390(Pt 2):419-26. PubMed ID: 15901238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.